Inflammatory predictors of mortality in the scandinavian simvastatin survival study

Background and hypothesis: The predictive value of specific markers of infection and autoimmunity for coronary events, such as the effects of statins on inflammation, is still controversial.

[1]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[2]  G. Niccoli,et al.  Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease; pathophysiological implications. , 2001, European heart journal.

[3]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[4]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[5]  P. Ridker,et al.  Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. , 1999, Circulation.

[6]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[7]  P. Ridker,et al.  Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. , 1998, Circulation.

[8]  A. Camm,et al.  Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. , 1998, Circulation.

[9]  W. Erl,et al.  HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. , 1997, Journal of the American College of Cardiology.

[10]  P. Libby,et al.  The unstable atheroma. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[11]  E. Gurfinkel,et al.  Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study , 1997, The Lancet.

[12]  S. Ogawa,et al.  C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. , 1997, Circulation.

[13]  L H Kuller,et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[14]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[15]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[16]  G. Bellomo,et al.  Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Evidence for new antigenic epitopes formed in vivo independently from lipid peroxidation. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[17]  L. Kuller,et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[18]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[19]  D. Strachan,et al.  Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors , 1995, BMJ.

[20]  Gram Jb,et al.  The Scandinavian Simvastatin Survival Study (4S) , 1995 .

[21]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[22]  A. Zeiher,et al.  Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. , 1995, Circulation.

[23]  G. Bellomo,et al.  Presence of autoantibodies against oxidatively modified low‐density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low‐density lipoprotein oxidation , 1995, Journal of hypertension.

[24]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[25]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[26]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[27]  F. Falaschi,et al.  [Autoantibodies against oxidised low density lipoproteins in patients with coronary disease]. , 1994, Presse medicale.

[28]  D. Strachan,et al.  Relation of Helicobacter pylori infection and coronary heart disease. , 1994, British heart journal.

[29]  G. Finardi,et al.  Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. , 1993, Coronary artery disease.

[30]  M. Leinonen,et al.  Chronic Chlamydia pneumoniae Infection as a Risk Factor for Coronary Heart Disease in the Helsinki Heart Study , 1992, Annals of Internal Medicine.

[31]  P. Limburg,et al.  Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. , 1991, Biochimica et biophysica acta.

[32]  G. Ciliberto,et al.  Dual control of C‐reactive protein gene expression by interleukin‐1 and interleukin‐6. , 1989, The EMBO journal.

[33]  A. Bankhurst,et al.  Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. , 1989, International journal of immunopharmacology.

[34]  M. Gimbrone,et al.  Inducible Endothelial Functions in Inflammation and Coagulation , 1987, Seminars in thrombosis and hemostasis.

[35]  P. Lipsky,et al.  Sterol metabolism and lymphocyte responsiveness: inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation. , 1981, Journal of immunology.

[36]  Young Ja,et al.  Clinical and necropsy findings in rupture of the myocardium. A review of forty-three cases. , 1963 .

[37]  J. Young,et al.  Clinical and necropsy findings in rupture of the myocardium. A review of forty-three cases. , 1963, Scottish medical journal.